Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY5R | Q15761 | 11/20 | 0.42 |
| ▸ | GNRHR | P30968 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | TACR1 | P25103 | 1/20 | 0.39 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26969745 | 0.84 | HDAC1 (0.41) | NPY5R | |
| SCHEMBL26969777 | 0.84 | HTR6 (0.40) | NPY5RGNRHRTACR1 | |
| SCHEMBL25231173 | 0.83 | NPY5R (0.38) | NPY5RGNRHRTACR1ALDH1A1 | |
| SCHEMBL25238614 | 0.83 | NOTUM (0.42) | NPY5RLMNANOTUMALDH1A1GAA | |
| SCHEMBL26969695 | 0.82 | HDAC1 (0.48) | NPY5R | |
| SCHEMBL26969782 | 0.82 | NOTUM (0.41) | NPY5RLMNANOTUMHTTALDH1A1 | |
| SCHEMBL26969766 | 0.81 | NPY5R (0.38) | NPY5RGNRHRTACR1ALDH1A1GAA | |
| SCHEMBL25232157 | 0.81 | NPY5R (0.41) | NPY5RKDM4ELMNAL3MBTL1MEN1 | |
| SCHEMBL26969707 | 0.81 | TSHR (0.38) | NPY5RTACR1ALDH1A1GAAMAPT | |
| SCHEMBL25240823 | 0.80 | MEN1 (0.40) | NPY5RKDM4ELMNAL3MBTL1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230416262-A1 | TRPML MODULATORS | CASMA THERAPEUTICS, INC. | 2023-12-28 | — | — | US | disclosed |
| EP-4192957-A2 | TRPML MODULATORS | Casma Therapeutics, Inc. (US) | 2023-06-14 | — | — | EP | disclosed |
| CN-116113698-A | TRPML modulators | 卡斯玛治疗公司 | 2023-05-12 | — | — | CN | disclosed |
| WO-2022032073-A2 | TRPML MODULATORS | CASMA THERAPEUTICS, INC. (US) | 2022-02-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230416262-A1 | TRPML MODULATORS | TRPM2, TRPM4, TRPM5 | NPY5R 681/4885GNRHR 1711/4885KDM4E 2480/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.